[go: up one dir, main page]

AR084457A1 - Derivados de biciclo[3,2,1]octilamida - Google Patents

Derivados de biciclo[3,2,1]octilamida

Info

Publication number
AR084457A1
AR084457A1 ARP110104844A ARP110104844A AR084457A1 AR 084457 A1 AR084457 A1 AR 084457A1 AR P110104844 A ARP110104844 A AR P110104844A AR P110104844 A ARP110104844 A AR P110104844A AR 084457 A1 AR084457 A1 AR 084457A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
nhr3
nhc
heteroaryl
Prior art date
Application number
ARP110104844A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR084457A1 publication Critical patent/AR084457A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Rheumatology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente proporciona derivados de biciclo[3,2,1]octilamida o una de sus sales farmacéuticamente aceptables; y composiciones farmacéuticas y sus métodos de uso. Los compuestos son útiles en el tratamiento de trastornos del SNC: cognitivos, neurodegenerativos (psiquiátricos o neurológicos).Reivindicación 1: Un compuesto que tiene la fórmula (1), en donde: L es -NHCO- o -CONH-; y R1 y R2 son cada uno, de modo independiente, alquilo, cicloalquilo, cetocicloalquilo, heterociclilo, arilo o heteroarilo, que está opcionalmente mono-, di- o trisustituido, de modo independiente, con alquilo, alcoxi, halógeno, ciano, nitro, trifluoroalquilo, amino, alquilamino, dialquilamino, acilo, arilo, heteroarilo, heterociclilo, heterociclil-R3, -NHR3, -N(alquil)R3, -C(O)NHR3, -C(O)N(alquil)R3, -NHC(O)R3, -N(alquil)C(O)R3, -OH u -OR3, en donde: R3 es alquilo C1-6 o cicloalquilo C1-6, que está opcionalmente sustituido con halógeno, -CN, -NH2, -NH(alquilo C1-3), -N(alquilo C1-3)2, alquil C1-3-heterociclilo, alquil C1-3-carbamato, -C(O)NH(alquilo C1-3), -C(O)N(alquilo C1-3)2, -NHC(O)-alquilo C1-3, -N(alquilo C1-3)-C(O)-alquilo C1-3, OH u -O-alquilo C1-6; o una de sus sales farmacéuticamente aceptables.
ARP110104844A 2010-12-22 2011-12-21 Derivados de biciclo[3,2,1]octilamida AR084457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426379P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
AR084457A1 true AR084457A1 (es) 2013-05-15

Family

ID=46314466

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104844A AR084457A1 (es) 2010-12-22 2011-12-21 Derivados de biciclo[3,2,1]octilamida

Country Status (30)

Country Link
US (3) US8921370B2 (es)
EP (2) EP2654422B1 (es)
JP (2) JP5992436B2 (es)
KR (1) KR101840076B1 (es)
CN (2) CN105348185B (es)
AP (1) AP3758A (es)
AR (1) AR084457A1 (es)
AU (2) AU2011348188B2 (es)
BR (1) BR112013015592A8 (es)
CA (1) CA2821937A1 (es)
CO (1) CO6741203A2 (es)
CR (1) CR20130309A (es)
DO (1) DOP2013000142A (es)
EA (1) EA026362B1 (es)
EC (1) ECSP13012788A (es)
GE (1) GEP20156219B (es)
GT (1) GT201300164A (es)
IL (1) IL226981A (es)
MA (1) MA34819B1 (es)
MX (2) MX2013007104A (es)
MY (1) MY169432A (es)
NZ (2) NZ705710A (es)
PE (1) PE20141529A1 (es)
PH (1) PH12013501340A1 (es)
SG (1) SG191317A1 (es)
TN (1) TN2013000253A1 (es)
TW (1) TWI538905B (es)
UA (1) UA109802C2 (es)
WO (1) WO2012088365A1 (es)
ZA (2) ZA201304624B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33479A (es) 2010-07-02 2012-01-31 Gilead Sciences Inc Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento
PT2588450T (pt) 2010-07-02 2017-08-03 Gilead Sciences Inc Derivados do ácido naft-2-ilacético para tratamento da sida
AR084457A1 (es) * 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
EP2763980B1 (en) * 2011-09-16 2018-04-25 H. Lundbeck A/S Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
JP5911638B2 (ja) 2012-04-20 2016-04-27 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
US11083725B2 (en) 2014-10-24 2021-08-10 St. Jude Children's Research Hospital Coordinated metabolic reprogramming in response to productive viral infections
BR112017023764A2 (pt) * 2015-05-05 2018-07-31 Bayer Pharma AG derivados de ciclohexano substituído por amido
WO2016205304A1 (en) * 2015-06-16 2016-12-22 Signal Pharmaceuticals, Llc Methods of treatment using substituted diaminopyrimidyl compounds
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) * 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
JP2020522553A (ja) * 2017-06-07 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ａｔｆ４経路阻害剤としての化合物
EP3649106A1 (en) * 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
PH12020550028B1 (en) 2017-08-09 2024-05-24 Denali Therapeutics Inc Compounds, compositions and methods
US12139478B2 (en) 2017-09-01 2024-11-12 Denali Therapeutics Inc. Compounds, compositions and methods
BR112020008834A2 (pt) 2017-11-02 2020-12-22 Calico Life Sciences Llc Moduladores da via de estresse integrada
UY37957A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3704089B1 (en) * 2017-11-02 2023-07-19 Calico Life Sciences LLC Modulators of the integrated stress pathway
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
TW202430498A (zh) 2018-10-11 2024-08-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
MA54953A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
WO2020167994A1 (en) 2019-02-13 2020-08-20 Denali Therapeutics Inc. Compounds, compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296310A1 (en) 1997-07-18 1999-01-28 Werner Tuckmantel Bicyclic metabotropic glutamate receptor ligands
PE20001236A1 (es) * 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
MXPA01012445A (es) 1999-06-02 2003-09-10 Nps Pharma Inc Antagonistas de receptor metabotropico de glutamato, y su uso para tratar enfermedades del sistema nervioso central.
EP1214303A1 (en) * 1999-08-31 2002-06-19 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
UA77391C2 (en) * 1999-11-12 2006-12-15 Biogen Inc Polycycloalkylpurines as antagonists of adenosine receptors
DE602004021206D1 (de) 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
WO2010011570A1 (en) 2008-07-25 2010-01-28 H. Lundbeck A/S Adamantyl diamide derivatives and uses of same
AR084457A1 (es) * 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida

Also Published As

Publication number Publication date
CA2821937A1 (en) 2012-06-28
AU2011348188B2 (en) 2016-06-16
JP2016164157A (ja) 2016-09-08
TN2013000253A1 (en) 2014-11-10
CN103369961A (zh) 2013-10-23
AP3758A (en) 2016-07-31
PH12013501340A1 (en) 2019-10-07
NZ705710A (en) 2016-09-30
EP2654422A1 (en) 2013-10-30
AU2016203192A1 (en) 2016-06-09
JP5992436B2 (ja) 2016-09-14
TWI538905B (zh) 2016-06-21
MX2013007104A (es) 2013-08-15
BR112013015592A2 (pt) 2016-07-12
TW201307291A (zh) 2013-02-16
CO6741203A2 (es) 2013-08-30
CN103369961B (zh) 2015-11-25
KR20130140801A (ko) 2013-12-24
US20120190686A1 (en) 2012-07-26
AU2016203192B2 (en) 2018-01-18
JP6087006B2 (ja) 2017-03-01
US8921370B2 (en) 2014-12-30
CN105348185A (zh) 2016-02-24
EP2654422B1 (en) 2017-08-02
GT201300164A (es) 2015-01-16
SG191317A1 (en) 2013-07-31
DOP2013000142A (es) 2013-10-15
US20170217950A1 (en) 2017-08-03
EA201390908A1 (ru) 2013-12-30
US9656975B2 (en) 2017-05-23
US20150057289A1 (en) 2015-02-26
GEP20156219B (en) 2015-01-12
KR101840076B1 (ko) 2018-03-19
NZ612000A (en) 2015-05-29
WO2012088365A1 (en) 2012-06-28
MA34819B1 (fr) 2014-01-02
AP2013006984A0 (en) 2013-07-31
BR112013015592A8 (pt) 2018-01-16
ZA201304624B (en) 2014-12-23
IL226981A (en) 2017-11-30
UA109802C2 (xx) 2015-10-12
AU2011348188A1 (en) 2013-07-04
MX349132B (es) 2017-07-13
CN105348185B (zh) 2018-02-16
PE20141529A1 (es) 2014-11-19
EA026362B1 (ru) 2017-03-31
EP3263566A1 (en) 2018-01-03
JP2014508128A (ja) 2014-04-03
CR20130309A (es) 2014-01-09
MY169432A (en) 2019-04-09
EP2654422A4 (en) 2014-05-14
ECSP13012788A (es) 2013-09-30
ZA201406059B (en) 2016-06-29

Similar Documents

Publication Publication Date Title
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR072839A1 (es) Derivados adamantil diamida y usos de los mismos
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR061206A1 (es) Pirido[3,2-e]pirazinas, su uso como inhibidores de la fosfodiesterasa 10, y procesos para prepararlas
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR063311A1 (es) Compuestos organicos
AR081390A1 (es) Compuestos de morfolina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el antagonismo del receptor mineralocorticoide (mra)
AR056470A1 (es) Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR065015A1 (es) Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR071531A1 (es) Compuesto cristalino heteromonociclico
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR084507A1 (es) Derivados de indazoliltriazol
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR076775A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
AR068466A1 (es) Cianoisoquinolina
AR070469A1 (es) Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.

Legal Events

Date Code Title Description
FB Suspension of granting procedure